FGFR1 and pulmonary fibrosis: Earlier kinase activity assays showed that YTH‐60 has the best inhibitory effect on FGFR1, thus we choose FGFR1 as the target of drug action and used the clinical drug Nintedanib as a positive control and evaluated the effects of YTH‐60 against pulmonary fibrosis in in vivo studies.